This paper is in the following e-collection/theme issue:

Diabetes Surveillance and Epidemiology (32) Diabetes (220) Health Services Research (517) Cardiovascular Disease Prevention (165) Secondary Use of Clinical Data for Research and Surveillance (411)

Published on in Vol 9 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/58137, first published .
Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Authors of this article:

Xuan Wang1 Author Orcid Image ;   Anna M Plantinga2 Author Orcid Image ;   Xin Xiong3 Author Orcid Image ;   Sara J Cromer4 Author Orcid Image ;   Clara-Lea Bonzel5 Author Orcid Image ;   Vidul Panickan5 Author Orcid Image ;   Rui Duan3 Author Orcid Image ;   Jue Hou6 Author Orcid Image ;   Tianxi Cai3 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Tseng P, Zeng B, Hsu C, Hung C, Carvalho A, Stubbs B, Chen Y, Chen T, Lei W, Chen J, Su K, Shiue Y, Liang C. The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis. BMC Medicine 2025;23(1) View